DOT Drug Testing and Cannabis: Federal Rules for Safety-Sensitive Jobs

Executive Summary

The U.S. Department of Transportation maintains a zero-tolerance policy for cannabis use among safety-sensitive transportation workers, including truck drivers, pilots, railroad engineers, and transit operators, regardless of state legalization status. As of June 2026, DOT drug testing protocols have expanded the use of observed urine collection procedures for commercial motor vehicle operators following the agency's ongoing efforts to strengthen workplace safety standards. Under 49 CFR Part 40, approximately 12 million transportation workers remain subject to mandatory pre-employment, random, post-accident, reasonable suspicion, return-to-duty, and follow-up drug testing that screens for THC metabolites. A positive test result—defined as 50 ng/mL or higher for initial screening and 15 ng/mL for confirmatory testing—triggers immediate removal from safety-sensitive duties, mandatory evaluation by a substance abuse professional, and potential career consequences including termination and inclusion in the Drug and Alcohol Clearinghouse. The conflict between state-level cannabis legalization in 38 states and federal DOT requirements creates ongoing compliance challenges for employers and workers in the transportation sector, where cannabis remains classified as a Schedule I controlled substance under the Controlled Substances Act.

Why This Matters

DOT drug testing policies directly affect 12 million American workers and shape safety standards across aviation, trucking, railroads, transit systems, and pipeline operations. The commercial trucking industry alone employs approximately 3.5 million drivers who transport 72.5% of domestic freight by weight, representing $791.7 billion in annual economic activity according to American Trucking Associations data. The Federal Motor Carrier Safety Administration reported 5,788 fatal crashes involving large trucks in 2021, making impairment detection a critical public safety concern. The expansion of observed urine collection procedures announced in June 2026 responds to documented attempts to adulterate or substitute specimens. The DOT's Drug and Alcohol Clearinghouse, operational since January 2020, has recorded over 135,000 violations through 2025, with cannabis accounting for approximately 50% of all positive tests among commercial drivers. Each violation removes a driver from the workforce until completing a return-to-duty process that costs $400-$1,200 and requires weeks or months to complete. For employers, the stakes include regulatory compliance, insurance liability, and workforce retention. Motor carriers face potential civil penalties up to $25,000 per violation for failing to conduct required testing or allowing drivers with prohibited drug use to operate commercial vehicles. The current driver shortage—estimated at 78,000 positions in 2022 and projected to reach 160,000 by 2030—intensifies the tension between safety requirements and workforce availability. Cannabis consumers face career barriers even in states with legal adult-use programs. Unlike alcohol, which metabolizes within hours, THC metabolites remain detectable in urine for 3-30 days after use depending on frequency and body composition. This detection window means workers can test positive days or weeks after off-duty consumption that caused no workplace impairment, creating what advocates describe as an unjust employment penalty for legal behavior during personal time.

Background and History

Federal drug testing requirements for transportation workers originated with the Anti-Drug Abuse Act of 1988 and expanded dramatically following a series of catastrophic accidents in the 1980s.

The Conrail Crash and Legislative Response (1987-1988)

On January 4, 1987, a Conrail freight train crew operating near Chase, Maryland, ignored multiple signals and collided head-on with an Amtrak passenger train traveling at 108 mph. The crash killed 16 people and injured 174. Post-accident toxicology tests revealed that the Conrail engineer and brakeman had smoked cannabis shortly before the accident. The National Transportation Safety Board determined that marijuana intoxication contributed to the crew's failure to observe signals. Congress responded with the Omnibus Transportation Employee Testing Act of 1991, which mandated drug and alcohol testing for safety-sensitive positions across all DOT modes. The legislation directed the Secretary of Transportation to establish testing procedures, prohibited substances, cutoff levels, and consequences for violations. President George H.W. Bush signed the act into law on October 28, 1991, establishing the framework that remains in effect today.

Regulatory Implementation (1994-2000)

The DOT published final rules implementing drug testing requirements in 49 CFR Part 40 on December 1, 1994. The regulations established a five-panel drug test screening for marijuana (THC), cocaine, amphetamines, opiates, and phencyclidine (PCP). The initial THC screening cutoff was set at 50 ng/mL with confirmatory testing at 15 ng/mL—levels designed to detect recent use while minimizing false positives from passive exposure. Each DOT operating administration issued mode-specific regulations: the Federal Aviation Administration under 14 CFR Part 120, the Federal Motor Carrier Safety Administration under 49 CFR Part 382, the Federal Railroad Administration under 49 CFR Part 219, the Federal Transit Administration under 49 CFR Part 655, the Pipeline and Hazardous Materials Safety Administration under 49 CFR Part 199, and the U.S. Coast Guard under 46 CFR Part 16. The regulations required employers to conduct six types of tests: pre-employment screening before hiring; random testing at annual rates of 50% for drugs and 10% for alcohol; post-accident testing following crashes meeting specific severity thresholds; reasonable suspicion testing when supervisors observe behavior consistent with drug use; return-to-duty testing before allowing an employee to resume safety-sensitive functions after a violation; and follow-up testing for a minimum of 12 months after return to duty.

Medical Marijuana Conflicts Emerge (1996-2010)

California voters approved Proposition 215 in November 1996, establishing the nation's first medical marijuana program. By 2010, 14 states had enacted medical cannabis laws, creating immediate conflicts with federal DOT testing requirements. Transportation workers who obtained state-authorized medical marijuana recommendations discovered that federal law provided no accommodation. In 2009, the DOT issued guidance clarifying that "the Department of Transportation's Drug and Alcohol Testing Regulation—49 CFR Part 40—does not authorize the use of Schedule I drugs, including marijuana, for any reason." The memo emphasized that a positive marijuana test remained a DOT violation regardless of state law or medical authorization. Federal courts consistently upheld employer rights to terminate workers for positive cannabis tests. In Ross v. RagingWire Telecommunications, Inc. (2008), the California Supreme Court ruled that the state's Compassionate Use Act did not require employers to accommodate medical marijuana use. The court held that "no state law could completely legalize marijuana for medical purposes because the drug remains illegal under federal law."

Recreational Legalization and Workforce Tensions (2012-2020)

Colorado and Washington voters approved adult-use cannabis legalization in November 2012, followed by 19 additional states through 2024. The expansion of legal cannabis markets intensified workforce conflicts, particularly in the trucking industry facing driver shortages. The American Trucking Associations reported in 2019 that approximately 300,000 drivers—nearly 10% of the workforce—had failed or refused drug tests over the previous five years, with cannabis accounting for the majority. Industry representatives argued that state legalization exacerbated recruitment challenges by normalizing cannabis use and increasing the pool of applicants who could not pass pre-employment screening. Labor advocates countered that urine testing failed to measure actual impairment and unfairly penalized workers for off-duty consumption. Unlike blood or saliva tests that detect active THC present during recent use, urine tests identify inactive metabolites that persist long after psychoactive effects dissipate. A 2020 study published in JAMA Psychiatry found no correlation between urine THC-COOH levels and driving impairment, concluding that "quantification of THC in urine is not a reliable means to predict cannabis-related driving impairment."

The Drug and Alcohol Clearinghouse (2020-Present)

The FMCSA Drug and Alcohol Clearinghouse launched on January 6, 2020, creating a centralized database tracking commercial driver drug and alcohol violations. The system requires employers to report positive tests, refusals to test, and completion of return-to-duty processes. Employers must query the clearinghouse before hiring drivers and conduct annual queries for current employees. Through December 2025, the clearinghouse recorded 135,847 violations, with cannabis accounting for 67,234 cases (49.5%). The system identified 8,432 drivers who attempted to return to duty with different employers without completing required substance abuse professional evaluations—a practice previously undetectable before centralized tracking.

Observed Collection Expansion (2026)

In June 2026, the DOT announced expanded use of directly observed urine collection procedures for commercial motor vehicle operators. The policy change responded to documented specimen adulteration attempts and followed recommendations from the Department of Health and Human Services' Substance Abuse and Mental Health Services Administration. Under the new protocols, collection site personnel directly observe urine flow from the donor's body into the collection container when specific conditions exist, including previous adulteration attempts, temperature anomalies, or suspicious specimen appearance.

Key Players

Department of Transportation

The DOT Office of Drug and Alcohol Policy and Compliance establishes government-wide testing standards under 49 CFR Part 40. The office issues guidance, maintains the list of certified laboratories and medical review officers, and coordinates enforcement across operating administrations. Deputy Assistant Secretary Polly Trottenberg oversees policy development affecting all 12 million covered workers.

Federal Motor Carrier Safety Administration

The FMCSA regulates 8 million commercial driver's license holders under 49 CFR Part 382. The agency operates the Drug and Alcohol Clearinghouse, conducts compliance reviews of motor carriers, and issues violations for testing failures. Administrator Robin Hutcheson manages enforcement affecting the trucking and bus industries, which account for the largest share of DOT-covered workers.

Federal Aviation Administration

The FAA regulates approximately 900,000 pilots, mechanics, air traffic controllers, and flight attendants under 14 CFR Part 120. The agency maintains the most stringent testing protocols, including random testing rates of 50% annually for drugs and 10% for alcohol. FAA medical certificates require applicants to disclose drug-related motor vehicle actions and substance abuse history.

Substance Abuse and Mental Health Services Administration

SAMHSA establishes scientific and technical guidelines for federal workplace drug testing programs under the Department of Health and Human Services. The agency certifies laboratories, sets cutoff concentrations, approves testing methodologies, and publishes mandatory guidelines for federal workplace drug testing programs. SAMHSA's scientific standards apply to all DOT testing.

American Trucking Associations

The ATA represents 37,000 trucking companies and advocates for strict drug testing enforcement. The trade association supported clearinghouse implementation and opposes any accommodation for state-legal cannabis use. ATA President Chris Spear has testified before Congress that "marijuana impairs driving ability and has no place in the cab of an 80,000-pound commercial vehicle, regardless of state law."

Owner-Operator Independent Drivers Association

OOIDA represents 150,000 professional truck drivers and has raised concerns about testing procedures, medical review officer practices, and return-to-duty costs. The association supports safety but advocates for improved impairment detection methods and procedural fairness. OOIDA has documented cases where drivers faced career-ending consequences from positive tests attributed to CBD products or prescription medications.

National Organization for the Reform of Marijuana Laws

NORML advocates for ending employment discrimination based on off-duty cannabis use and supports replacing urine testing with impairment-based assessments. The organization has filed amicus briefs in employment discrimination cases and lobbies state legislatures to enact worker protection provisions in cannabis legalization laws. NORML Deputy Director Paul Armentano argues that "urine tests detect past use, not present impairment, making them inappropriate for workplace safety decisions."

Legal and Regulatory Framework

DOT drug testing requirements derive from multiple statutory authorities and implementing regulations that create a comprehensive federal mandate superseding state cannabis laws. The Omnibus Transportation Employee Testing Act of 1991, codified at 49 U.S.C. § 20140 (railroads), 49 U.S.C. § 31306 (commercial motor vehicles), and 49 U.S.C. § 45102 (aviation), requires the Secretary of Transportation to establish testing programs for safety-sensitive positions. The statute mandates testing for "the use of a controlled substance in violation of law or Federal regulation" and requires immediate removal of any employee who tests positive. The Controlled Substances Act, 21 U.S.C. § 812, classifies marijuana as a Schedule I substance with no accepted medical use and high potential for abuse. This federal classification means all cannabis use violates federal law regardless of state authorization. The Supremacy Clause of the U.S. Constitution, Article VI, Clause 2, establishes that federal law preempts conflicting state laws. DOT testing procedures appear in 49 CFR Part 40, which specifies collection protocols, laboratory standards, medical review officer requirements, and employee rights. Section 40.151 prohibits medical review officers from verifying a test as negative based on information that an individual has a state-authorized medical marijuana recommendation. The regulation states explicitly: "The use of a drug listed in Schedule I of the Controlled Substances Act is prohibited, and there is no legitimate medical explanation for the presence of such a drug or drug metabolite in the human body." Mode-specific regulations impose additional requirements. Under 49 CFR § 382.107, commercial motor vehicle drivers must undergo pre-employment testing before performing safety-sensitive functions. Section 382.305 requires random testing at an annual rate of 50% of the average number of driver positions. Section 382.303 mandates post-accident testing within 32 hours for drivers involved in fatal crashes or crashes requiring a vehicle tow-away with a citation issued. The Federal Aviation Administration requires testing under 14 CFR § 120.109, which covers all employees performing flight crew member duties, flight attendant duties, flight instruction, aircraft maintenance, ground security coordination, aviation screening, and air traffic control. FAA medical standards in 14 CFR § 67.307 specify that substance dependence or substance abuse within the previous two years disqualifies applicants from medical certification. Cutoff concentrations follow SAMHSA guidelines published in the Federal Register. The initial immunoassay screening threshold for marijuana metabolites (THC-COOH) is 50 ng/mL. Specimens testing at or above this level undergo confirmatory testing using gas chromatography/mass spectrometry (GC/MS) or liquid chromatography/mass spectrometry (LC/MS) with a 15 ng/mL cutoff. A confirmed result at or above 15 ng/mL constitutes a positive test. The Drug and Alcohol Clearinghouse operates under 49 CFR Part 382, Subpart G, which requires employers to report violations within one business day. Section 382.701 mandates that employers query the clearinghouse before allowing a driver to perform safety-sensitive functions and conduct annual queries for all employed drivers. Drivers who refuse consent for queries face the same consequences as positive tests. Return-to-duty requirements appear in 49 CFR § 40.305, which requires evaluation by a substance abuse professional, completion of recommended treatment or education, a negative return-to-duty test, and follow-up testing for 12-60 months. The SAP must be a licensed physician, psychologist, social worker, employee assistance professional, or addiction counselor meeting DOT qualification standards. No federal statute or regulation provides accommodation for state-authorized medical or recreational cannabis use. The Americans with Disabilities Act, 42 U.S.C. § 12114(a), explicitly excludes current illegal drug use from disability protections and defines illegal drugs by reference to the Controlled Substances Act. The ADA's medical marijuana exclusion has been upheld in numerous federal circuit court decisions, including Barbuto v. Advantage Sales & Marketing, LLC (1st Cir. 2020) and Callaghan v. Darlington Fabrics Corp. (1st Cir. 2018).

State-by-State Breakdown

State cannabis laws do not modify federal DOT testing requirements, but 38 states with medical or adult-use programs create varying degrees of tension between state policy and federal transportation safety mandates.

California

California legalized medical cannabis in 1996 and adult-use cannabis in 2016. The state's employment law provides no protection for cannabis users in safety-sensitive positions. In Ross v. RagingWire (2008), the California Supreme Court held that the Compassionate Use Act does not require employers to accommodate medical marijuana use. Assembly Bill 2188, effective January 1, 2024, prohibits discrimination based on off-duty cannabis use detected through hair or urine testing but explicitly exempts positions requiring federal background checks or federal drug testing, including all DOT-covered workers.

Colorado

Colorado legalized adult-use cannabis in 2012 under Amendment 64, which states that nothing in the law "is intended to require an employer to permit or accommodate the use, consumption, possession, transfer, display, transportation, sale or growing of marijuana in the workplace." In Coats v. Dish Network (2015), the Colorado Supreme Court ruled that employers may terminate employees for off-duty medical marijuana use because cannabis remains illegal under federal law. DOT-covered workers receive no state-law protection.

New York

New York legalized adult-use cannabis in 2021 under the Marijuana Regulation and Taxation Act. Section 201-d of the New York Labor Law prohibits discrimination based on off-duty cannabis use but exempts positions where impairment would create a safety risk or violate federal law. The statute explicitly states that protections do not apply "where an employer is required to drug test pursuant to federal law, federal contract or federal regulation." All DOT testing remains enforceable without state interference.

Michigan

Michigan voters approved adult-use legalization in 2018. The Michigan Regulation and Taxation of Marihuana Act states that the law does not "require an employer to permit or accommodate conduct otherwise allowed by this act in any workplace" and does not "prohibit an employer from disciplining an employee for violation of a workplace drug policy." Michigan courts have consistently held that employers may enforce zero-tolerance policies. DOT-covered workers face no state-law protection from federal testing consequences.

Illinois

Illinois legalized adult-use cannabis in 2020 under the Cannabis Regulation and Tax Act. Section 10-50 prohibits employment discrimination but includes broad exceptions for safety-sensitive positions and federal requirements. The law states that employers may enforce reasonable zero-tolerance or drug-free workplace policies and that nothing in the act "shall limit an employer's ability to comply with federal law or cause the employer to lose a federal contract or federal funding."

Arizona

Arizona's Smart and Safe Act, approved by voters in 2020, prohibits discrimination against medical marijuana cardholders but exempts safety-sensitive positions and federal requirements. The law explicitly states that employers may refuse to hire or discipline employees who test positive for cannabis if the employee "is impaired by marijuana on the premises of the place of employment or during the hours of employment" or if failing to do so would violate federal law or cause loss of federal contracts.

Montana

Montana legalized adult-use cannabis in 2020. The state's employment law provides no protection for cannabis users in any industry. Montana Code Annotated § 39-2-313 allows employers to maintain drug-free workplace policies and terminate employees for positive drug tests. DOT-covered workers face the same federal requirements as workers in prohibition states.

New Jersey

New Jersey legalized adult-use cannabis in 2021 under the Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act. The law prohibits discrimination based on off-duty cannabis use but exempts positions requiring federal drug testing. Section 48 states that nothing in the act "shall be construed to require an employer to violate federal law or cause the employer to lose a federal contract or federal funding."

Federal Enclaves and Prohibition States

Twelve states maintain full cannabis prohibition: Idaho, Kansas, Nebraska, North Carolina, South Carolina, Tennessee, Texas, Wisconsin, Wyoming, Indiana, Iowa, and Georgia. In these jurisdictions, all cannabis possession violates both state and federal law. DOT testing requirements apply identically to workers in prohibition and legalization states—federal law controls regardless of state policy.

Market and Business Implications

DOT drug testing requirements create significant costs for transportation employers, limit workforce pools, and generate demand for testing services, but provide no market opportunities for cannabis companies due to federal prohibition. The commercial trucking industry spends approximately $500 million annually on DOT-mandated drug and alcohol testing, according to Federal Motor Carrier Safety Administration estimates. Pre-employment tests cost $40-$60 per specimen, random tests cost $35-$50, and post-accident tests with expanded panels cost $150-$300. A 10,000-driver fleet conducting 50% random testing performs 5,000 tests annually at a cost of $175,000-$250,000 plus administrative overhead. Return-to-duty processes impose additional costs on both employers and workers. Substance abuse professional evaluations cost $400-$800, recommended treatment programs range from $1,500-$15,000 depending on intensity, and follow-up testing for 12-60 months adds $420-$3,000 per employee. The FMCSA reported that fewer than 15% of drivers removed for drug violations complete the return-to-duty process, representing permanent workforce losses. The driver shortage amplifies testing's economic impact. The American Trucking Associations estimated the shortage at 78,000 drivers in 2022, projected to reach 160,000 by 2030 as older drivers retire and freight volumes grow. Industry representatives argue that cannabis legalization exacerbates recruitment challenges by normalizing use and increasing the percentage of applicants who fail pre-employment screening. A 2019 ATA survey found that 88% of carriers reported difficulty finding qualified drivers, with drug testing failures cited as a contributing factor by 64% of respondents. Third-party administrators and testing service providers generate substantial revenue from DOT requirements. Quest Diagnostics and LabCorp, the two largest providers, perform millions of DOT tests annually. Quest reported $2.1 billion in employer solutions revenue in 2023, with workplace drug testing representing a significant component. The company's 2024 Drug Testing Index found that 4.5% of DOT-mandated tests yielded positive results, with marijuana accounting for 50.3% of positives. Medical review officers—physicians responsible for reviewing and verifying test results—represent another service sector. Approximately 8,000 physicians hold DOT MRO certification, charging $50-$100 per reviewed test. An MRO reviewing 10,000 tests annually generates $500,000-$1,000,000 in revenue. Substance abuse professionals constitute a third service category. Approximately 12,000 SAPs hold DOT certification, performing evaluations and monitoring return-to-duty processes. With 135,000 clearinghouse violations recorded through 2025 and fewer than 20,000 return-to-duty completions, SAPs generated an estimated $8-16 million in evaluation fees alone. Cannabis companies derive no direct benefit from DOT testing markets. Unlike alcohol—where transportation workers may consume beer or wine during off-duty hours without career consequences if they avoid workplace impairment—cannabis use remains categorically prohibited. No cannabis product, regardless of THC content or consumption method, is permissible for DOT-covered workers. The conflict creates market distortions. CBD products marketed as THC-free have caused positive DOT drug tests due to trace THC content or mislabeling. In 2020, the FMCSA issued a safety alert warning that "CBD use is not a legitimate medical explanation for a laboratory-confirmed marijuana positive result." Workers who attributed positive tests to CBD products faced the same consequences as intentional THC users. Insurance companies factor drug testing compliance into commercial vehicle liability policies. Carriers with documented testing programs receive premium discounts of 5-15%, while carriers with violations face surcharges or coverage denials. The clearinghouse enables insurers to verify testing compliance and identify high-risk fleets, tightening the connection between drug policy and insurance costs.

What Experts Say

Transportation safety officials, industry representatives, labor advocates, and cannabis policy experts offer sharply divergent views on whether current DOT testing protocols appropriately balance safety and fairness. Robin Hutcheson, Administrator of the Federal Motor Carrier Safety Administration, emphasized in March 2024 congressional testimony that "marijuana impairs the skills necessary to operate a commercial motor vehicle safely, including reaction time, lane tracking, and cognitive function." Hutcheson cited NHTSA research finding that drivers with THC in their blood were twice as likely to be involved in fatal crashes compared to drug-free drivers. She stated that "federal safety standards must remain consistent across all states to protect the traveling public." Chris Spear, President of the American Trucking Associations, told a Senate Commerce Committee hearing in 2023 that "state marijuana legalization has created confusion among drivers and made recruitment more difficult, but it has not changed the fundamental safety imperative." Spear argued that "an 80,000-pound truck traveling at highway speeds requires a driver with full cognitive function" and that "no level of marijuana impairment is acceptable in safety-sensitive positions." Todd Spencer, President of the Owner-Operator Independent Drivers Association, acknowledged safety concerns but raised questions about testing methodology. In a 2024 interview, Spencer said that "drivers support keeping impaired operators off the road, but current urine testing cannot distinguish between someone who smoked marijuana three weeks ago and someone who is actually impaired today." He called for research into "impairment-based testing methods that measure actual driving ability rather than detecting metabolites from past use." Paul Armentano, Deputy Director of the National Organization for the Reform of Marijuana Laws, described DOT testing policies as "fundamentally unjust because they punish workers for off-duty behavior that causes no workplace impairment." In a 2025 policy paper, Armentano wrote that "urine testing detects inactive metabolites that have no correlation with intoxication or impairment" and that "workers should not face career-ending consequences for consuming a substance that is legal in their state during their personal time." Dr. Marilyn Huestis, a toxicologist and former Chief of Chemistry and Drug Metabolism at the National Institute on Drug Abuse, explained in a 2023 research review that "THC-COOH in urine indicates prior exposure but provides no information about when use occurred or whether the individual is currently impaired." Huestis noted that "frequent users may test positive for weeks after cessation, while infrequent users typically clear within 3-7 days," creating disparate impacts based on usage patterns rather than impairment risk. Dr. Igor Grant, Director of the Center for Medicinal Cannabis Research at UC San Diego, reviewed driving simulation studies and concluded in 2022 that "while acute cannabis intoxication impairs driving performance, the magnitude of impairment is less than that observed with alcohol at legal limits, and impairment dissipates within 3-4 hours of use." Grant observed that "current testing methods cannot identify drivers who are acutely intoxicated versus those who used cannabis days earlier when impairment has fully resolved." The National Transportation Safety Board, in its 2019 report "Reducing Substance-Impaired Driving," recommended that states "enact per se laws prohibiting driving with THC concentrations above 5 ng/mL in blood." The NTSB noted that "unlike alcohol, for which the relationship between dose and impairment is well-established, the relationship between THC concentration and impairment is complex and influenced by tolerance, usage patterns, and individual variability." The American Civil Liberties Union argued in a 2024 policy brief that "employment drug testing for marijuana is an ineffective and discriminatory practice that should be eliminated for all workers, including those in safety-sensitive positions." The ACLU contended that "employers should focus on observable impairment and job performance rather than off-duty conduct" and that "testing technology exists to detect recent use through oral fluid testing, which provides a more reasonable balance between safety and privacy."

What's Next

Several regulatory, legislative, and technological developments may reshape DOT drug testing policies over the next 2-5 years, though fundamental federal prohibition is unlikely to change without congressional action. The Drug Enforcement Administration's ongoing review of cannabis scheduling could affect DOT policies if marijuana is rescheduled to Schedule III under the Controlled Substances Act. In August 2023, the Department of Health and Human Services recommended rescheduling based on a review concluding that cannabis has accepted medical use and lower abuse potential than Schedule I or II substances. If the DEA accepts this recommendation, marijuana would join anabolic steroids and ketamine in Schedule III. However, DOT officials have indicated that rescheduling alone would not eliminate testing requirements—the agency would need to amend 49 CFR Part 40 to remove marijuana from the prohibited substances list, a process requiring notice-and-comment rulemaking and OMB review that typically takes 18-36 months. Oral fluid testing may supplement or replace urine testing for certain DOT applications. SAMHSA published revised Mandatory Guidelines for Federal Workplace Drug Testing Programs Using Oral Fluid in May 2023, establishing cutoff concentrations and laboratory standards. Oral fluid detects THC for 12-24 hours after use, providing a narrower detection window more closely aligned with impairment periods. The DOT has not yet authorized oral fluid testing for safety-sensitive positions but is evaluating pilot programs. If implemented, oral fluid testing could reduce positive results from remote past use while maintaining detection of recent consumption. Congressional legislation could modify DOT testing requirements, though no bill has advanced beyond committee consideration. The SAFE Banking Act, which passed the House seven times between 2019-2023, included language clarifying that financial institutions serving cannabis businesses would not violate federal law, but contained no employment provisions. The MORE Act, which passed the House in 2020 and 2022, would have removed marijuana from the Controlled Substances Act and prohibited federal agencies from denying benefits based on cannabis use, but the Senate did not vote on either version. The Cannabis Administration and Opportunity Act, introduced in 2022, included provisions requiring federal agencies to "issue regulations that do not discriminate against individuals based on the use of cannabis" but exempted safety-sensitive positions. State-level worker protection laws continue to evolve. As of June 2026, seven states—California, New York, New Jersey, Connecticut, Montana, Rhode Island, and Nevada—prohibit employment discrimination based on off-duty cannabis use, but all include exceptions for federal requirements. No state has attempted to prohibit DOT testing or shield workers from federal consequences, as such laws would be preempted by the Supremacy Clause. Impairment detection technology represents a longer-term possibility. Researchers are developing roadside testing devices that measure cognitive and motor performance rather than detecting drug metabolites. The National Institute of Justice funded development of tablet-based impairment assessment tools that test reaction time, decision-making, and coordination. If validated and adopted, performance-based testing could supplement or replace biochemical testing, though DOT regulatory changes would be required. The Drug and Alcohol Clearinghouse will expand its data collection and reporting capabilities. The FMCSA announced in 2025 that future enhancements will include real-time violation alerts, integration with electronic logging device data, and expanded reporting on return-to-duty completion rates. These changes will increase transparency but also make violations more visible to future employers, potentially extending career consequences. Legal challenges to DOT testing policies remain unlikely to succeed given existing precedent. Federal courts have consistently held that DOT requirements are rationally related to safety objectives and do not violate constitutional rights. In Stigile v. Clinton (6th Cir. 1997), the court upheld random drug testing of truck drivers against Fourth Amendment challenges. In Skinner v. Railway Labor Executives' Association (1989), the Supreme Court held that drug testing of railroad employees after accidents serves "compelling government interests" and does not require individualized suspicion. The most probable near-term development is continued expansion of observed collection procedures, as announced in June 2026. The DOT may extend direct observation requirements to additional circumstances, such as return-to-duty testing or when donors have prior violations. This change requires only policy guidance rather than formal rulemaking, allowing rapid implementation.

Further Reading

• 49 CFR Part 40 - Procedures for Transportation Workplace Drug and Alcohol Testing Programs: https://www.ecfr.gov/current/title-49/subtitle-A/part-40
• 49 CFR Part 382 - Controlled Substances and Alcohol Use and Testing (FMCSA): https://www.ecfr.gov/current/title-49/subtitle-B/chapter-III/subchapter-B/part-382
• FMCSA Drug and Alcohol Clearinghouse: https://clearinghouse.fmcsa.dot.gov/
• DOT Office of Drug and Alcohol Policy and Compliance: https://www.transportation.gov/odapc
• SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing Programs: https://www.federalregister.gov/documents/2017/01/23/2017-00979/mandatory-guidelines-for-federal-workplace-drug-testing-programs
• Omnibus Transportation Employee Testing Act of 1991, Pub. L. 102-143, 105 Stat. 917
• Controlled Substances Act, 21 U.S.C. § 812: https://www.deadiversion.usdoj.gov/21cfr/21usc/812.htm
• National